NTRK1 and carcinoma: HER2 alterations (point mutations or increased expression) occurred with similar frequencies in samples with activating mutations in receptor tyrosine kinases FGFR2/3, in tumors with RAS/RAF gene mutations, and in FGFR2/3- and RAS/RAF-wild type carcinomas (Figure 2 and Figure 3).